Minovia Therapeutics Ltd., an Israeli company running the first ever cell therapy trial to treat a mitochondrial disease, has dosed the first participant in a phase I/II study of a treatment for the rare pediatric condition Pearson syndrome. A second patient will be dosed in three weeks. Five of the seven patients that will ultimately participate in the trial have already been recruited, fueling hope that the study will be completed by year-end or earlier.